Drug Profile
Research programme: small molecule and peptide therapeutics - Enzo Biochem
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Enzo Biochem
- Class Antihyperglycaemics; Antineoplastics; Peptides; Skin disorder therapies; Small molecules
- Mechanism of Action LDL receptor modulators; LDL receptor related protein modulators; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Hair disorders; Skin disorders
- No development reported Bone disorders; Diabetes mellitus; Osteonecrosis; Osteoporosis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Bone-disorders in USA (PO)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Osteonecrosis in USA (PO)